MASS Quote, Financials, Valuation and Earnings

Quantum-Si has a net margin of -174.66% compared to 908 Devices's net margin of -3216.39%. 908 Devices's return on equity of -38.6% beat Quantum-Si's return on equity of -35.65%.

908 Devices has a consensus price target of --, signalling upside risk potential of 175.75%. On the other hand Quantum-Si has an analysts' consensus of -- which suggests that it could grow by 150.97%. Given that 908 Devices has higher upside potential than Quantum-Si, analysts believe 908 Devices is more attractive than Quantum-Si.

908 Devices has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Quantum-Si has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

908 Devices has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quantum-Si offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 908 Devices pays -- of its earnings as a dividend. Quantum-Si pays out -- of its earnings as a dividend.

908 Devices quarterly revenues are $16.8M, which are larger than Quantum-Si quarterly revenues of $787K. 908 Devices's net income of -$29.3M is lower than Quantum-Si's net income of -$25.3M. Notably, 908 Devices's price-to-earnings ratio is -- while Quantum-Si's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 908 Devices is 1.25x versus 81.13x for Quantum-Si. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -174.66% compared to 908 Devices's net margin of -18.58%. 908 Devices's return on equity of -38.6% beat Retractable Technologies's return on equity of -16.83%.

908 Devices has a consensus price target of --, signalling upside risk potential of 175.75%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that 908 Devices has higher upside potential than Retractable Technologies, analysts believe 908 Devices is more attractive than Retractable Technologies.

908 Devices has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.979, suggesting its more volatile than the S&P 500 by 97.877%.

908 Devices has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 908 Devices pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

908 Devices quarterly revenues are $16.8M, which are larger than Retractable Technologies quarterly revenues of $10.3M. 908 Devices's net income of -$29.3M is lower than Retractable Technologies's net income of -$1.9M. Notably, 908 Devices's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 908 Devices is 1.25x versus 0.50x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -174.66% compared to 908 Devices's net margin of -4291.67%. 908 Devices's return on equity of -38.6% beat Catheter Precision's return on equity of -65.84%.

908 Devices has a consensus price target of --, signalling upside risk potential of 175.75%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 506.06%. Given that Catheter Precision has higher upside potential than 908 Devices, analysts believe Catheter Precision is more attractive than 908 Devices.

908 Devices has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

908 Devices has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 908 Devices pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

908 Devices quarterly revenues are $16.8M, which are larger than Catheter Precision quarterly revenues of $96K. 908 Devices's net income of -$29.3M is lower than Catheter Precision's net income of -$4.1M. Notably, 908 Devices's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 908 Devices is 1.25x versus 0.88x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -174.66% compared to 908 Devices's net margin of -17.98%. 908 Devices's return on equity of -38.6% beat Xtant Medical Holdings's return on equity of -35.98%.

908 Devices has a consensus price target of --, signalling upside risk potential of 175.75%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 525%. Given that Xtant Medical Holdings has higher upside potential than 908 Devices, analysts believe Xtant Medical Holdings is more attractive than 908 Devices.

908 Devices has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

908 Devices has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 908 Devices pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

908 Devices quarterly revenues are $16.8M, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. 908 Devices's net income of -$29.3M is lower than Xtant Medical Holdings's net income of -$5M. Notably, 908 Devices's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 908 Devices is 1.25x versus 0.42x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.